The estimated Net Worth of Patrick Cambridge Equities,... is at least 772 百万$ dollars as of 29 June 2020. Patrick Equities owns over 3,710,000 units of NantKwest Inc stock worth over 771,661,868$ and over the last 9 years Patrick sold NK stock worth over 0$.
Patrick has made over 4 trades of the NantKwest Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Patrick bought 3,710,000 units of NK stock worth 44,965,200$ on 29 June 2020.
The largest trade Patrick's ever made was buying 3,710,000 units of NantKwest Inc stock on 29 June 2020 worth over 44,965,200$. On average, Patrick trades about 860,108 units every 253 days since 2015. As of 29 June 2020 Patrick still owns at least 23,750,750 units of NantKwest Inc stock.
You can see the complete history of Patrick Equities stock trades at the bottom of the page.
Over the last 9 years, insiders at NantKwest Inc have traded over 20,345,739$ worth of NantKwest Inc stock and bought 4,163,265 units worth 55,365,252$ . The most active insiders traders include Patrick Cambridge Equities,...、Steve Gorlin、Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of 5,362,832$. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth 4,873,500$.
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
NantKwest Inc executives and other stock owners filed with the SEC include: